TELANGMHealthcare·Medical Devices#111 in industry

TELA Bio, Inc.

Reports in 15d· 2026-05-12

-18.4% · 90d

$0.80

+0.10 (+14.26%)

After-Hours $0.83(+0.03)

News

No News Yet

Press releases and SEC filings for TELA will appear here as they are published.

Check back later for updates

Key Data

Market Cap$35.8M

Open$0.69

Prev Close$0.70

Day Range$0.64 – $0.83

52W Range$0.50 – $2.20

Volume791,844

P/E (TTM)—

EPS$-0.83

Dividend Yield—

Beta0.99

Profit Margin-48.37%

Revenue Growth18.20%

Price Target$2.25(+181.4%)

Next Earnings2026-05-12(15d)

Analyst Ratings

Strong Buy5 analysts

Buy 4Hold 1Sell 0

About

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Healthcare · Medical Devices

www.telabio.com